ICON plc CEO Barry Balfe and CFO Nigel Clerkin will present at the Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 12:30pm GMT; Balfe will participate at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026 at 1:20pm ET.
ICLR · Icon PLC
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 35%
- Last earnings
- Oct 28, 2026
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
ICON reported record net business wins of $3.15 billion, up 51% year-over-year, with a net book-to-bill of 1.56 times. Revenue was just over $2 billion, down 2.9% year-over-year, while adjusted EBITDA rose 3% to $337 million and adjusted EPS was $2.66. The board approved a new $750 million share repurchase authorization.
ICON plc sold $2.15 billion of senior unsecured notes on August 13, 2026 through its subsidiary ICON Investments Six Designated Activity Company, and used the proceeds to repay the $900.0 million Senior Secured Term Loan, redeem the $750.0 million May 2027 Notes, and repay the $500.0 million Bridge Secured Credit Facility. The Board also raised the share buyback authorization to $750.0 million on October 20, 2026.
ICON plc reported third-quarter 2026 revenue of $2,024.8 million, a decrease of 2.9% on quarter three 2025, and GAAP net income of $122.1 million. It updated full-year 2026 guidance, with revenue expected in the range of $8,100 - $8,200 million. Adjusted diluted earnings per share guidance is in the range of $10.35 - $10.65.
ICON plc will release third quarter 2026 financial results after market close on Tuesday, October 27, 2026, then discuss performance on a conference call and webcast on Wednesday, October 28, 2026 at 8:00am ET.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ICLR
this stock
Icon PLC
|
$13.78B | +4.5% | +19.8% | 31.2 | 3.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$255.19B | +18.9% | +14.5% | 36.3 | 1.3% |
|
DHR
Danaher Corp
|
$160.10B | -0.6% | +8.5% | 37.2 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$54.33B | +1.9% | +10.4% | 46.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.43B | +28.9% | +6.4% | 34.5 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 24
ICON plc CEO Barry Balfe and CFO Nigel Clerkin will present at the Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 12:30pm GMT; Balfe will participate at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026 at 1:20pm ET.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ICLR | -5.1% | +2.7% | +37.9% | -9.9% | +4.5% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +0.4% | +9.0% | +43.5% | -4.7% | -0.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.